Patents by Inventor Zoltan Szekely
Zoltan Szekely has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11933340Abstract: Fastener assemblies and nut plate assemblies include a plate member, a shell member and a floating nut disposed within the shell member and defining a bore configured to receive a threaded fastener. The fastener assemblies and nut plate assemblies also include at least one magnetic component disposed within the shell member and configured to switch the nut plate assembly between a locked configuration and an unlocked configuration.Type: GrantFiled: January 24, 2022Date of Patent: March 19, 2024Assignee: Enduralock, LLCInventors: Harold Hess, Deeptesh Selvaraj, Igor Komsitsky, Armando Perez, Zoltan Szekely
-
Patent number: 11752215Abstract: The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: GrantFiled: March 12, 2021Date of Patent: September 12, 2023Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITYInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Zoltan Szekely
-
Publication number: 20220235812Abstract: Fastener assemblies and nut plate assemblies include a plate member, a shell member and a floating nut disposed within the shell member and defining a bore configured to receive a threaded fastener.Type: ApplicationFiled: January 24, 2022Publication date: July 28, 2022Inventors: Harold Hess, Deeptesh Selvaraj, Igor Komsitsky, Armando Perez, Zoltan Szekely
-
Publication number: 20210299270Abstract: The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: March 12, 2021Publication date: September 30, 2021Applicants: Rutgers, The State University of New Jersey, Georgetown UniversityInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Zoltan Szekely
-
Publication number: 20190151464Abstract: The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: March 17, 2017Publication date: May 23, 2019Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Zoltan Szekely
-
Patent number: 9566349Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: GrantFiled: January 8, 2015Date of Patent: February 14, 2017Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Publication number: 20150202322Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: ApplicationFiled: January 8, 2015Publication date: July 23, 2015Inventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Patent number: 9085604Abstract: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.Type: GrantFiled: December 13, 2007Date of Patent: July 21, 2015Assignees: University of Maryland, Baltimore, The United States of America as represented by the Secretary of the Department of Health and Human Services, The United Sates of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Thomas Conrads, Timothy Veenstra, Maria Michejda
-
Patent number: 9079936Abstract: Derivatives of a novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed. In particular embodiments, the glycopeptide comprises D-proline.Type: GrantFiled: August 18, 2009Date of Patent: July 14, 2015Assignees: University of Maryland, Baltimore, The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, The United States of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Maria Michejda
-
Patent number: 8912146Abstract: Derivatives of bladder epithelial antiproliferative factor and methods of using them are disclosed. In specific embodiments, the glycopeptide compositions are useful for the treatment and/or prevention of medical conditions, including cancer. In other embodiments, there are compositions and methods related to treatment of bladder conditions. In particular embodiments, the glycopeptide comprises D-pipecolic acid or L-pipecolic acid.Type: GrantFiled: August 18, 2009Date of Patent: December 16, 2014Assignees: University of Maryland, Baltimore, The Department of Health and Human Services, The United States of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Piotr Kaczmarek, Maria Michejda
-
Publication number: 20140335189Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: ApplicationFiled: July 29, 2014Publication date: November 13, 2014Inventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Patent number: 8791234Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: GrantFiled: October 14, 2011Date of Patent: July 29, 2014Assignee: Rutgers, The State University of New JerseyInventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Patent number: 8680056Abstract: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.Type: GrantFiled: May 3, 2007Date of Patent: March 25, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Thomas Conrads, Timothy Veenstra, Maria Michejda
-
Publication number: 20130302249Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: ApplicationFiled: October 14, 2011Publication date: November 14, 2013Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Publication number: 20120094933Abstract: Derivatives of bladder epithelial antiproliferative factor and methods of using them are disclosed. In specific embodiments, the glycopeptide compositions are useful for the treatment and/or prevention of medical conditions, including cancer. In other embodiments, there are compositions and methods related to treatment of bladder conditions. In particular embodiments, the glycopeptide comprises D-pipecolic acid or L-pipecolic acid.Type: ApplicationFiled: August 18, 2009Publication date: April 19, 2012Inventors: Christopher Michejda, Maria Michejda, Susan K. Keay, Zoltan Szekely, Piotr Kaczmarek
-
Publication number: 20100041588Abstract: Derivatives of a novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed. In particular embodiments, the glycopeptide comprises D-proline.Type: ApplicationFiled: August 18, 2009Publication date: February 18, 2010Inventors: Susan K. Keay, Christopher Michejda, Maria Michejda, Zoltan Szekely
-
Patent number: 7605125Abstract: A conjugate of formula: V—(Y)a—Z-T: (I), T-X—B—(Y)a—Z-T?: (II), V—(Y)a Z—(Y?)a V?: (III), T-X—B—(Y)a—Z—(Y?)a—X?—B?-T?: (IV), V—(Y)a—Z—(Y?)a—X—B-T: (V), V—(Y)a—Z—X—B—Z?—(Y?)a—(V?)b: (VI), or (W)a—(Y)b—[(Z)c—(Y?)d—(X—B)e—(Y?)f—(Z?)g]h—(Y . . .Type: GrantFiled: February 27, 2003Date of Patent: October 20, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Zoltan Szekely, Humcha Krishnamurthy Hariprakasha, Marek W. Cholody, Christopher Michejda
-
Publication number: 20090148505Abstract: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.Type: ApplicationFiled: December 13, 2007Publication date: June 11, 2009Applicant: University of MarylandInventors: Susan K. Keay, Christopher Michejda, Zoltan Szekely, Thomas P. Conrads, Timothy D. Veenstra, Maria Michejda
-
Publication number: 20090118349Abstract: The present invention relates to (i) conjugates comprising two DNA alkylating subunits linked by a moiety fitting to the minor groove of the DNA, (ii) to their preparation and (iii) to their use in cancer therapy. The alkylating subunits are especially cytotoxic under hypoxic conditions found in cancer cells. The compounds of the present invention and compositions thereof are useful in the treatment of cancer in a mammal, both alone or in a combination with other anti-cancer agents (e.g. checkpoint abrogators) and/or radiation. They may also be used as cytotoxic units for gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme-prodrug therapy (ADEPT). The present invention provides the compounds of Formula (I), Formula (II) and Formula (III): for treating cancer in a mammal.Type: ApplicationFiled: August 16, 2008Publication date: May 7, 2009Applicant: ONCO-PHARMAKON INCORPORATEDInventors: Zoltan Szekely, Matthew Gerard McDonnell
-
Publication number: 20090069220Abstract: A conjugate of formula: V—(Y)a-Z-T??(I), T-X—B—(Y)a-Z-T???(II), V—(Y)a-Z-(Y?)a—V???(III), T-X—B—(Y)a-Z-(Y?)a—X?—B?-T???(IV), V—(Y)a-Z-(Y?)a—X—B-T??(V), V—(Y)a-Z-X—B-Z?-(Y?)a—(V?)b??(VI), or (W)a—(Y)b-[(Z)c-(Y?)d—(X—B)e—(Y?)f-(Z?)g]h-(Y??)i—(W?)j??(VII), in which W and W? are independently a DNA intercalator or terminal subunit, V and V? are independently a DNA intercalator, X and X? are independently a DNA alkylator, B and B? are the same or different and each is a heteroaromatic residue that is attached to the N-terminus of an alkylator subunit (X or X?), Y, Y?, Y? and Y?? are independently a linker, T and T? are independently terminal subunits, Z and Z? are independently a polyamide group that binds to the minor groove of DNA, a, b, c, d, f, g, i, and j are independently 0 to 5, and e and h are independently 1 to 5, a composition comprising a conjugate of any of formulae (I)-(VII) and a carrier, and a method for treating cancer in a mammal comprising administering an effective amount ofType: ApplicationFiled: September 16, 2008Publication date: March 12, 2009Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPAInventors: Zoltan Szekely, Humcha Krishnamurthy Hariprakasha, Marek W. Cholody, Christopher Michejda